Morgan Stanley Forecasts Strong Price Appreciation for Belite Bio (NASDAQ:BLTE) Stock

by · The Markets Daily

Belite Bio (NASDAQ:BLTE – Get Free Report) had its price target boosted by analysts at Morgan Stanley from $191.00 to $201.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s target price would suggest a potential upside of 14.09% from the stock’s current price.

BLTE has been the topic of several other research reports. Bank of America assumed coverage on Belite Bio in a report on Monday, January 26th. They set a “buy” rating and a $195.00 target price on the stock. Wall Street Zen lowered shares of Belite Bio from a “hold” rating to a “sell” rating in a report on Sunday, January 4th. Cantor Fitzgerald boosted their target price on shares of Belite Bio from $200.00 to $266.00 and gave the stock an “overweight” rating in a research note on Tuesday. BTIG Research set a $187.00 target price on shares of Belite Bio in a research report on Wednesday, December 3rd. Finally, Maxim Group set a $200.00 price target on shares of Belite Bio in a report on Tuesday, December 2nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $198.63.

View Our Latest Report on BLTE

Belite Bio Trading Down 0.8%

BLTE stock traded down $1.41 during trading on Tuesday, hitting $176.17. 112,166 shares of the stock traded hands, compared to its average volume of 226,447. The stock has a market cap of $6.61 billion, a price-to-earnings ratio of -91.76 and a beta of -1.46. Belite Bio has a one year low of $49.00 and a one year high of $200.00. The company has a 50 day simple moving average of $168.66 and a 200 day simple moving average of $122.59.

Belite Bio (NASDAQ:BLTE – Get Free Report) last announced its earnings results on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.18. As a group, analysts predict that Belite Bio will post -1.17 earnings per share for the current fiscal year.

Institutional Trading of Belite Bio

Several institutional investors and hedge funds have recently made changes to their positions in BLTE. Caitong International Asset Management Co. Ltd grew its stake in shares of Belite Bio by 54,800.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 549 shares of the company’s stock worth $88,000 after purchasing an additional 548 shares during the period. Seven Fleet Capital Management LP acquired a new position in shares of Belite Bio during the 4th quarter worth about $1,465,000. ADAR1 Capital Management LLC bought a new stake in shares of Belite Bio in the 4th quarter valued at about $6,373,000. Wellington Management Group LLP acquired a new stake in shares of Belite Bio in the 4th quarter valued at approximately $991,000. Finally, Squadron Capital Management LLC bought a new position in Belite Bio during the 4th quarter worth approximately $4,159,000. Institutional investors own 0.53% of the company’s stock.

Trending Headlines about Belite Bio

Here are the key news stories impacting Belite Bio this week:

  • Positive Sentiment: Cantor Fitzgerald raised its price target to $266 and moved BLTE to an “overweight” rating — a bullish analyst call that signals ~50% upside vs. the recent stock level and can drive buying interest. Cantor Fitzgerald upgrade (Benzinga)
  • Positive Sentiment: Management is targeting a Q2 2026 NDA submission for the Stargardt therapy and is planning $200M–$250M of commercialization spend; the company also reported a surge in cash reserves — together these raise the odds of a near‑term regulatory catalyst and show readiness to commercialize if approved. NDA target & commercialization plan (Seeking Alpha)
  • Positive Sentiment: Belite reported preliminary Q4/2025 results and an EPS of ($0.38) that beat consensus (-$0.56). Management released slides and a corporate update that support the NDA timeline and cash commentary — earnings beat tends to be a direct short‑term positive. Preliminary results & corporate update (GlobeNewswire)
  • Neutral Sentiment: Belite will present at the Leerink Global Healthcare Conference — useful for investor visibility but not an immediate fundamental change. Leerink conference participation (Business Insider/Markets)
  • Neutral Sentiment: Full Q4 earnings call transcript is available for investors who want detailed color on milestones, cash and commercialization plans. Earnings call transcript (Seeking Alpha)
  • Neutral Sentiment: Short‑interest data reported appears anomalous (shows zero shares), so there’s no clear signal of mounting short pressure from that dataset; treat that item with caution.
  • Negative Sentiment: Analyst models still expect negative FY EPS (sell‑side estimate ~ -1.17) and the planned $200M–$250M commercialization spend, while showing preparedness, also implies high near‑term cash burn if commercialization proceeds — financing and execution risk remain potential downsides.

Belite Bio Company Profile

(Get Free Report)

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.

Read More